Finance

In this article AXP Pilot’s founders Jessica McKellar (CTO), Waseem Daher (CEO), Jeff Arnold (COO) Pilot Accounting start-up Pilot raised a new round of funding from Jeff Bezos and other Silicon Valley investors to help small businesses outsource back-office tasks. The San Francisco-based company closed a $100 million funding round this week, doubling its valuation
0 Comments
Chinese Foreign Ministry spokeswoman Hua Chunying attends a news conference in Beijing, China January 21, 2021. Carlos Garcia Rawlins | Reuters BEIJING — China slapped sanctions on U.K. entities on Friday, saying that Britain’s sanctions on Chinese individuals over alleged human rights abuses in Xinjiang were based on “lies and disinformation.” The Ministry of Foreign
0 Comments
Darren Westlake, co-founder and CEO of Crowdcube, at a fintech conference in London, on April 12, 2017. Simon Dawson | Bloomberg via Getty Images LONDON — British start-up crowdfunding platforms Crowdcube and Seedrs agreed Thursday to terminate their £140 million ($192 million) merger, a day after regulators raised competition concerns with the deal. The U.K.
0 Comments
Wells Fargo Securities’ Chris Harvey is building a major part of his strategy on a consumer comeback. From hotels to casinos to restaurants, many of this year’s winning trades will involve spending outside the home, the firm’s head of equity strategy predicts. “We really want exposure to the consumer,” Harvey told CNBC’s “Trading Nation” on
0 Comments
Canaccord Genuity’s Tony Dwyer is temporarily dialing back his appetite for stocks. On the one-year anniversary of the Covid-19 bottom, he’s telling investors the market is in “no man’s land.” “We’re in this period where the Russell 1000 growth mega cap stocks aren’t oversold anymore and the cyclical or economic recovery theme isn’t extreme overbought
0 Comments
Take a look at some of the biggest movers in the premarket: AstraZeneca (AZN) – The drugmaker said a U.S. study showed its Covid-19 vaccine had 79% efficacy in preventing symptomatic illness, 100% effectiveness against critical disease and hospitalization, and did not pose a higher risk of blood clots. AstraZeneca shares gained 2.2% in premarket
0 Comments